Your browser doesn't support javascript.
CVSARRP: A framework to predict the risk of adverse to severe adverse reactions for 10855 diseases after COVID-19 vaccination.
Jin, Jiahuan; Li, Jie.
  • Jin J; Research Center of Bioinformatics, Faculty of Computing, Harbin Institute of Technology, Harbin, Heilongjiang Province, China.
  • Li J; Research Center of Bioinformatics, Faculty of Computing, Harbin Institute of Technology, Harbin, Heilongjiang Province, China.
Heliyon ; 9(4): e14828, 2023 Apr.
Article in English | MEDLINE | ID: covidwho-2264775
ABSTRACT
COVID-19 vaccines greatly reduce the risk of infection with SARS-CoV-2. However, some people have adverse reactions after vaccination, and these can sometimes be severe. Gender, age, vaccines, and especially certain diseases histories are related to severe adverse reactions following COVID-19 vaccination. However, there are thousands of diseases and only some are known to be related to these severe adverse reactions. The risk of severe adverse reactions with other diseases remains unknown. Therefore, there is a need for predictive studies to provide improved medical care and minimize risk. Herein, we analyzed the statistical results of existing COVID-19 vaccine adverse reaction data and proposed a COVID-19 vaccine severe adverse reaction risk prediction method, named CVSARRP. The performance of the CVSARRP method was tested using the leave-one-out cross-validation approach. The correlation coefficient between the predicted and real risk is greater than 0.86. The CVSARRP method predicts the risk from adverse reactions to severe adverse reactions after COVID-19 vaccination for 10855 diseases. People with certain diseases, such as central nervous system diseases, heart diseases, urinary system disease, anemia, cancer, and respiratory tract disease, among others, may potentially have increased of severe adverse reactions following vaccination against COVID-19 and experiencing adverse events.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines Language: English Journal: Heliyon Year: 2023 Document Type: Article Affiliation country: J.heliyon.2023.e14828

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines Language: English Journal: Heliyon Year: 2023 Document Type: Article Affiliation country: J.heliyon.2023.e14828